Boston Scientific Corporation $BSX Stake Lifted by Qsemble Capital Management LP

Qsemble Capital Management LP raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 64.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 127,966 shares of the medical equipment provider’s stock after acquiring an additional 50,313 shares during the quarter. Boston Scientific makes up about 1.0% of Qsemble Capital Management LP’s portfolio, making the stock its 6th biggest position. Qsemble Capital Management LP’s holdings in Boston Scientific were worth $12,202,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares in the last quarter. Rathbones Group PLC boosted its position in Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after acquiring an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC bought a new stake in Boston Scientific during the 4th quarter valued at $1,477,000. Kepler Cheuvreux Suisse SA bought a new stake in Boston Scientific during the 3rd quarter valued at $26,955,000. Finally, Waycross Partners LLC bought a new stake in Boston Scientific during the 4th quarter valued at $2,384,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 1.7%

Boston Scientific stock opened at $52.67 on Friday. The business has a fifty day moving average price of $63.40 and a 200-day moving average price of $81.79. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $78.27 billion, a price-to-earnings ratio of 22.04, a PEG ratio of 0.98 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of recent analyst reports. Raymond James Financial reissued an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. BTIG Research lowered their price objective on Boston Scientific from $90.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Barclays lowered their price objective on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. Evercore lowered their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, Oppenheimer set a $90.00 price objective on Boston Scientific in a research report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $93.91.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.